Alyve Review

What Alyve charges

• Tirzepatide: $283/mo — from, per month on the product page; a banner on every page of the same site quotes $329 a month for the same product
• Semaglutide: $183/mo — from, per month
• Tirzepatide: $249/mo — from, per month
• Semaglutide: $203/mo — from, per month
• Sermorelin: $129/mo — from, per month
• NAD+: $129/mo — from, per month
• Glutathione: $129/mo — from, per month

Two published prices for one product, and neither page yields

A promotional header on every page of the site quotes a monthly figure for compounded tirzepatide. The product page for that same compounded tirzepatide quotes a different, lower figure in its own hero.

Both render in the same fetch of the same page, so this is not a stale cache or a page one version behind. The banner does not match the sublingual tirzepatide product either, which carries a third figure.

Both are recorded here and neither is corrected. The seller has not reconciled them, so a reader should expect to be quoted whichever number the checkout applies rather than the one that drew them in.

It prices the form, not just the molecule

Semaglutide and tirzepatide each appear twice: once as a weekly injectable and once as needle-free daily drops, each with its own figure.

The injectable listings say what the money buys — a vial of a stated size, with a home kit included — rather than leaving the reader to guess whether supplies are extra.

Sermorelin, NAD+ and glutathione are priced individually in the same injectable format, so five separate compounds have a figure of their own here.

What it says it is, in its own words

Its safety page reads: "Important: Compounded medications have not been reviewed or approved by the FDA for safety, effectiveness, or quality. They are not FDA-approved drug products." That is the seller's own statement, printed in bold on its own site.

It also describes itself as "a clinical infrastructure and managed services organization (MSO). We do not employ physicians, practice medicine, or provide clinical care." Those are its words, quoted here rather than endorsed.

It names no dispensing pharmacy, only a pharmacy network, and it makes no claim about which states it serves.

Three signs the site is not finished

Three sublingual products carry a price and the label coming soon. Nothing here is filed against them, because a price for something you cannot buy is not a price — though marking them is better than pricing them silently.

Its terms of service still carry an unreplaced template placeholder in the date line, square brackets and all.

Combined with the banner disagreement, the picture is of a price sheet that changed and a site that did not fully follow.

How we verified this

• Read the banner and the product hero in the same fetch of the same page, confirmed both figures render, and recorded both without choosing between them.
• Filed the injectable and sublingual forms of each molecule as separate products, because the seller prices them separately.
• Declined to file the three sublingual products the seller marks coming soon, and read its terms page to the date line.
• Requested a deliberately meaningless address on this host in the same session and confirmed it returns a not-found response.
• Screened the brand against the live federal warning-letter table under three spellings of its name, pulling all 3,677 records in pages and filtering locally because the table's own search parameter is ignored, with a positive and a nonsense control in the same run. No letter.